Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; dosimetric findings

被引：0
|
作者：
Mok, S. [1 ]
Tay, Y. [1 ]
Ng, D. [1 ]
机构：
[1] Singapore Gen Hosp, Singapore, Singapore
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P603
引用
收藏
页码：S532 / S532
页数：1
相关论文
共 50 条
  • [21] SPECT/CT calibration using clinical dosimetry workstations for peptide receptor radionuclide therapy (PRRT) in patients treated with 177Lu-DOTATATE
    Mora Ramirez, E.
    Santoro, L.
    Trauchessec, D.
    Chouaf, S.
    Deshayes, E.
    Pouget, J.
    Kotzki, P.
    Bardies, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S809 - S810
  • [22] Lu-177-DOTATATE Peptide Receptor Radionuclide Therapy
    Abbott, Amanda
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2018, 46 (03) : 245 - 246
  • [23] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Swiha, Mina M.
    Sutherland, Duncan E. K.
    Sistani, Golmehr
    Khatami, Alireza
    Abazid, Rami M.
    Mujoomdar, Amol
    Wiseman, Daniele P.
    Romsa, Jonathan G.
    Reid, Robert H.
    Laidley, David T.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 225 - 236
  • [24] Effect of Peptide Receptor Radionuclide Therapy (PRRT) with tandem isotopes-90Y/177Lu-DOTATATE in patients with disseminated neuroendocrine tumors
    Kunikowska, J.
    Krolicki, L.
    Pawlak, D.
    Mikolajaczak, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S425 - S426
  • [25] Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors
    Abou Jokh Casas, E.
    Pombo Pasin, M. D.
    Pubul Nunez, V.
    Garrido Pumar, M.
    Blanco Freire, M. N.
    Cabezas, J.
    Cameselle, J.
    Berrios, M.
    Argibay, S.
    Ruibal Morell, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S597 - S598
  • [26] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Jie Zhang
    Qi Song
    Liang Cai
    Ying Xie
    Yue Chen
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1533 - 1543
  • [27] Impaired Kidney Function Is Associated with Higher Absorbed Dose to Organs-at-Risk in 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT)
    Marin, G.
    Karfis, I
    Levillain, H.
    Reynaert, N.
    Vandenberghe, S.
    Vanderlinden, B.
    Flamen, P.
    NEUROENDOCRINOLOGY, 2019, 108 : 221 - 221
  • [28] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Mina M. Swiha
    Duncan E. K. Sutherland
    Golmehr Sistani
    Alireza Khatami
    Rami M. Abazid
    Amol Mujoomdar
    Daniele P. Wiseman
    Jonathan G. Romsa
    Robert H. Reid
    David T. Laidley
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 225 - 236
  • [29] Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
    Bodei, Lisa
    Cremonesi, Marta
    Grana, Chiara M.
    Fazio, Nicola
    Iodice, Simona
    Baio, Silvia M.
    Bartolomei, Mirco
    Lombardo, Dario
    Ferrari, Mahila E.
    Sansovini, Maddalena
    Chinol, Marco
    Paganelli, Giovanni
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (12) : 2125 - 2135
  • [30] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    D. Levart
    E. Kalogianni
    B. Corcoran
    N. Mulholland
    G. Vivian
    EJNMMI Physics, 6
12345